GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » ROC %

PMCB (PharmaCyte Biotech) ROC % : -11.44% (As of Oct. 2024)


View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. PharmaCyte Biotech's annualized return on capital (ROC %) for the quarter that ended in Oct. 2024 was -11.44%.

As of today (2025-03-14), PharmaCyte Biotech's WACC % is 6.87%. PharmaCyte Biotech's ROC % is -22.84% (calculated using TTM income statement data). PharmaCyte Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


PharmaCyte Biotech ROC % Historical Data

The historical data trend for PharmaCyte Biotech's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCyte Biotech ROC % Chart

PharmaCyte Biotech Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -72.69 -70.44 -85.63 -125.85 -62.43

PharmaCyte Biotech Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -78.58 -58.97 -29.25 -17.12 -11.44

PharmaCyte Biotech ROC % Calculation

PharmaCyte Biotech's annualized Return on Capital (ROC %) for the fiscal year that ended in Apr. 2024 is calculated as:

ROC % (A: Apr. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Apr. 2023 ) + Invested Capital (A: Apr. 2024 ))/ count )
=-6.52 * ( 1 - 0% )/( (5.129 + 15.76)/ 2 )
=-6.52/10.4445
=-62.43 %

where

PharmaCyte Biotech's annualized Return on Capital (ROC %) for the quarter that ended in Oct. 2024 is calculated as:

ROC % (Q: Oct. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jul. 2024 ) + Invested Capital (Q: Oct. 2024 ))/ count )
=-4.424 * ( 1 - 0% )/( (43.554 + 33.765)/ 2 )
=-4.424/38.6595
=-11.44 %

where

Note: The Operating Income data used here is four times the quarterly (Oct. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaCyte Biotech  (NAS:PMCB) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, PharmaCyte Biotech's WACC % is 6.87%. PharmaCyte Biotech's ROC % is -22.84% (calculated using TTM income statement data). PharmaCyte Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


PharmaCyte Biotech ROC % Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaCyte Biotech Business Description

Traded in Other Exchanges
N/A
Address
3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb director 100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen director 299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K director
Carlos Trujillo director, officer: CFO 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner director, officer: Chairman, CEO, Pres and GC 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree director, officer: Chief Science Officer 12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099